• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    6/13/24 4:31:04 PM ET
    $ALZN
    $BNOX
    $CDT
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALZN alert in real time by email

    Gainers

    • Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million.
    • Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million.
    • Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million.
    • Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million.
    • Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million.
    • Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The market value of their outstanding shares is at $4.3 million.

    Losers

    • Alzamend Neuro (NASDAQ:ALZN) stock declined by 24.9% to $0.43 during Thursday's after-market session. The market value of their outstanding shares is at $3.1 million.
    • Nexalin Technology (NASDAQ:NXL) stock declined by 16.67% to $1.15. The company's market cap stands at $8.5 million.
    • Rezolute (NASDAQ:RZLT) shares declined by 15.7% to $4.35. The company's market cap stands at $174.5 million.
    • Conduit Pharmaceuticals (NASDAQ:CDT) shares fell 8.42% to $1.85. The market value of their outstanding shares is at $136.5 million.
    • PAVmed (NASDAQ:PAVM) stock fell 8.11% to $1.02. The company's market cap stands at $9.6 million.
    • Bionomics (NASDAQ:BNOX) shares declined by 7.99% to $0.76. The company's market cap stands at $8.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALZN
    $BNOX
    $CDT
    $KTRA

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    Rezolute Inc.
    $RZLT
    11/5/2024$12.00Outperform
    Wedbush
    Rezolute Inc.
    $RZLT
    8/27/2024$11.00Buy
    Guggenheim
    Vaxart Inc
    $VXRT
    8/15/2024$4.00Outperform
    Oppenheimer
    Rezolute Inc.
    $RZLT
    7/17/2024$13.00Buy
    BTIG Research
    More analyst ratings

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg's proprietary AI Signature Agent platform, evaluated CDT's portfolio of assets, including its solid-form patent portfolio and its licensed AstraZeneca compounds AZD1656 and AZD5658, against a database of approximately 1,700 rare disease signatures. The Company reports t

    3/23/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

    Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than 30 Oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapy approvals for various stages of multiple myeloma currently generating more than $16 billion in worldwide sales TAMPA, Fla., March 23, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strat

    3/23/26 7:45:00 AM ET
    $HURA
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

    Highlighting Positive Results in Comparison to Valchlor® and in Real-World Use PRINCETON, N.J., March 23, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that findings from recent supportive trials with HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) are being presented at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 26, 2026), which precedes the American Academy of Dermatology (AAD) Annual Meeting. Ellen Kim, MD, Director, Penn Cutane

    3/23/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Berg Edward B

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/20/26 3:16:03 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Cummings James F.

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/20/26 3:15:35 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Lo Steven

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/20/26 3:15:14 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:14:55 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/17/25 4:13:53 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    12/15/25 7:35:57 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    SEC Filings

    View All

    Alzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/20/26 4:30:20 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/18/26 4:53:07 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxart Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vaxart, Inc. (0000072444) (Filer)

    3/12/26 4:11:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Wedbush with a new price target

    Wedbush downgraded Rezolute from Outperform to Neutral and set a new price target of $1.00

    12/11/25 10:36:07 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bionomics Limited

    SC 13G - BIONOMICS LIMITED/FI (0001191070) (Subject)

    11/14/24 3:25:19 PM ET
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 16, 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Monday, March 30, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial r

    3/16/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

    3/12/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

    Conference Call and Webcast at 8:30 AM ETNEW YORK, March 12, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth quarter 2025 financial results.

    3/12/26 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ALZN
    $BNOX
    $CDT
    $KTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

    HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

    10/13/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology